Court rules against Teva in patent suit

Israeli generic drug developer says court ruled against it in a patent dispute with Eisai Co's over heartburn drug Aciphex
Associated Press|
PrintFind an error? Report us
Related Topics
Israeli generic drug developer Teva Pharmaceutical Industries Ltd. said Friday a court ruled against it in a patent dispute with Eisai Co's over the heartburn drug Aciphex.
The US District Court for the Southern District of New York upheld Eisai's patent on the drug, Teva said. Eisai sued Israel-based Teva in 2003 over its plans for a generic version of Aciphex. Teva had received Food and Drug Administration approval for the generic version.
Teva said it will appeal the court's decision.
Shares of Teva fell 83 cents, or 2.3 percent, to $39.12 in after-hours trading. In the regular trading session, shares rose $1.50, or 3.9 percent, to $39.95.
Comments
The commenter agrees to the privacy policy of Ynet News and agrees not to submit comments that violate the terms of use, including incitement, libel and expressions that exceed the accepted norms of freedom of speech.
""